Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. - sprookjes - yvandenbroek - TriplyDB

Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.

Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.

http://www.wikidata.org/entity/Q30492173

about

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration.Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration Clinical validity and utility of genetic risk scores in prostate cancer Improved prediction of complex diseases by common genetic markers: state of the art and further perspectives The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.Incorporation of personal single nucleotide polymorphism (SNP) data into a national level electronic health record for disease risk assessment, part 3: an evaluation of SNP incorporated national health information system of Turkey for prostate cance Impact of prostate-specific antigen on a baseline prostate cancer risk assessment including genetic risk.Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial.The Xu's chart for prostate biopsy: a visual presentation of the added value of biomarkers to prostate-specific antigen for estimating detection rates of prostate cancer.An epidemiological reappraisal of the familial aggregation of prostate cancer: a meta-analysis Genome-wide association studies of cancer.Pooled sample-based GWAS: a cost-effective alternative for identifying colorectal and prostate cancer risk variants in the Polish population.Context-dependent effects of genome-wide association study genotypes and macroenvironment on time to biochemical (prostate specific antigen) failure after prostatectomy.Prostate cancer in young men: an important clinical entity.Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy How can polygenic inheritance be used in population screening for common diseases?Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence.The use of genomic information to optimize cancer chemotherapy Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a "normal" prostate specific antigen and digital rectal examination Polygenic susceptibility to prostate and breast cancer: implications for personalised screening Impact of genotyping on outcome of prostatic biopsies: a multicenter prospective study.Screening for familial and hereditary prostate cancer.8q24 risk alleles in West African and Caribbean men.Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers.GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP)Population-based screening in the era of genomics Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer Prostate cancer risk-associated genetic markers and their potential clinical utility Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer.A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.Biomarkers in prostate cancer surveillance and screening: past, present, and future.Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes.Evaluation of reported prostate cancer risk-associated SNPs from genome-wide association studies of various racial populations in Chinese men.Genetic variants in association studies--review of strengths and weaknesses in study design and current knowledge of impact on cancer risk.Prostate cancer genomics, biology, and risk assessment through genome-wide association studies.

P2860

Q24289354-6A50B367-5D26-4B91-9FA9-4FB893D26A71 Q24289476-88D1D08C-00C5-462C-8AD3-B16BB802308F Q26746219-B4D12EF6-D54A-4100-85A1-10C7B2E294A2 Q26770167-30ADE9B7-D989-4C20-BEFD-F0539D9822B1 Q27025062-B6524877-1935-4B9A-BA34-C0879BDB5B5F Q30493284-703D8E8C-C4B8-4579-A823-8235A56C6F46 Q30504100-E51112D0-37DD-41AA-9C15-E55307FEBFFB Q30884955-85501A7D-8D20-429B-B6FF-581EE9311899 Q33585860-3B443815-8189-41DD-844F-A74026F24976 Q33883502-E84BFD8C-1829-4AB2-82E6-6BF26B9DA7E3 Q33922385-93DB66BC-4C18-42F2-8B9B-6F6E97616319 Q34071472-082D31D8-2249-4A7B-BA8B-76FFD33D1B59 Q34193988-758294B4-E537-4C54-B309-ADE71624B773 Q34245058-414C7834-D52D-4CDC-B1C3-AAE7AEEC9D1B Q34275499-801B7A5A-C0EB-405C-90AE-C2ADCB9370A1 Q34314644-BA7A7146-C781-4100-8416-38A4A137501B Q34323314-786A38D4-64E9-455C-B409-20E712971AF4 Q34327946-2C2306C6-DF60-4AA6-A55A-76059B5E198C Q34688123-55C2D626-C08E-4D79-A382-79319287EF3F Q34791981-0246C987-DC24-4FDA-AB92-7DD6E028843E Q34946649-80C6A4FA-D3CB-4630-ACBD-BF3E9C2101D2 Q34977428-A32591F2-D657-478E-8D8B-0414ECBA7969 Q35016946-57CC6299-56AC-4EA9-9B57-E50590E9DFB3 Q35861576-CFB0F19C-EC50-473B-B65F-C4C820FC4925 Q35942186-6D9E6BAB-B72C-457F-9313-0F9E13F448CD Q36097440-57111FC3-2B1F-4BBA-B357-920E16996006 Q36112373-977B9B23-BBC5-4595-A3AC-6EE1FB67484A Q36233914-D4EDB795-BAD4-49B5-A36F-493AEC7A7D73 Q36599573-4A4855E9-36A6-4467-A821-A3196C80CC44 Q37017011-9D276C8D-9C85-4AE3-8C67-947B4468AD49 Q37085446-9CD0074A-75B9-4E54-A543-498541C13CC0 Q37113165-043E7525-492F-41A3-B3F5-BA5C91641D50 Q37217578-93D48421-8477-400D-848B-056D7D62FA00 Q37253699-3ED62DCA-034D-4EE2-8670-834A806998AF Q37262639-95AED340-6E60-4337-93EB-6EA0BDD93CF9 Q37300931-D651840F-C7AB-4F96-A710-45A4669318CE Q37541989-6C7399D2-CABA-4B2A-8187-097DE3407622 Q37592171-00A4BF15-A15B-4A95-80F1-87A2B39A1033 Q37622914-B14545F1-F49B-4F0D-9DE1-44A3761C1017 Q37969803-E26FF8DC-F36B-4C32-A9B3-603905C911CB

P2860

Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.

http://www.wikidata.org/entity/Q30492173

description

2009 nî lūn-bûn

@nan

2009 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մարտին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Clinical utility of five genet ...... ate cancer risk and mortality.

@ast

Clinical utility of five genet ...... ate cancer risk and mortality.

@en

type

label

Clinical utility of five genet ...... ate cancer risk and mortality.

@ast

Clinical utility of five genet ...... ate cancer risk and mortality.

@en

prefLabel

Clinical utility of five genet ...... ate cancer risk and mortality.

@ast

Clinical utility of five genet ...... ate cancer risk and mortality.

@en

P1433

Q30492173-8A6EF01E-9845-4EDE-BD2F-AF0D1725A568

P1476

Q30492173-B5BC7FDA-A49F-404A-8C70-2C563539E324

P2093

Q30492173-246C54F9-7DF4-4F6C-9AE7-3582CECB3D7C

Q30492173-270CEC4D-F98A-4B1C-903C-57E80150FA33

Q30492173-3FD40AA6-59FA-40F7-8DCB-9625E13BBA7D

Q30492173-4A25D2AF-85C0-4F7C-B60B-A2E3F1C3D1D4

Q30492173-8369BE17-19B0-4EBF-8C97-B8A3C65EE84A

Q30492173-FFAEBAB3-01C6-4A83-9209-E62D0DECA661

P2860

Q30492173-0829CEB5-D9C4-4A7D-B275-821D4D262DAE

Q30492173-1606FEC0-10CA-4DC9-A5DD-09634A98A9DD

Q30492173-189AA13F-E44F-4A66-9FC4-610DDB91248F

Q30492173-1AB5B532-2BE0-46E9-82FC-1389813E6E4D

Q30492173-2323CCEB-89C0-4E79-A171-005FDC9A0B61

Q30492173-2E44A0C3-7A4E-45D8-9595-0D6ED102767B

Q30492173-3C7F4515-E898-4132-BB73-F69271A87C98

Q30492173-474863E0-2300-4962-98EF-872A78FF6DBC

Q30492173-4787CE4B-9ED2-4CDF-930E-512EB3F6C501

Q30492173-6AC52ED9-AEA3-48E9-B2D8-7E9634F4C413

P304

Q30492173-27C9ECB3-8DEC-47B9-956E-D7F24F17F162

P31

Q30492173-324CA18C-F26B-4381-AE47-F2ED8F57E890

P356

Q30492173-AF556569-5EA7-4A28-AC93-DF80B828FF7D

P433

Q30492173-31578AA2-951D-4421-A066-581A503464B6

P478

Q30492173-B30A8C99-CA93-447F-AED4-AFED48D37EC3

P50

Q30492173-6561D246-E28C-45F6-A63B-7558B7BC17E0

Q30492173-D6899222-C0C5-4068-8D63-1CBFFF2244C0

P577

Q30492173-9F9F0FD9-C2EA-4BF2-9293-CED4690CD935

P5875

Q30492173-9D80FBD7-40A2-46B6-BBFD-26618B198D4F

P698

Q30492173-E37F45C8-6381-4831-A467-E99368A82D2F

P932

Q30492173-B96C77DF-66DE-4A1F-A255-ED25E47B4C8F

P356

P1433

P1476

Clinical utility of five genet ...... ate cancer risk and mortality.

@en

P2093

Claudia A Salinas

http://www.w3.org/2001/XMLSchema#string

Daniel W Lin

http://www.w3.org/2001/XMLSchema#string

Erika M Kwon

http://www.w3.org/2001/XMLSchema#string

Janet L Stanford

http://www.w3.org/2001/XMLSchema#string

Joseph S Koopmeiners

http://www.w3.org/2001/XMLSchema#string

Ziding Feng

http://www.w3.org/2001/XMLSchema#string

P2860

Attributable risk percent in case-control studies

Cancer statistics, 2008

Multiple newly identified loci associated with prostate cancer susceptibility

Multiple loci identified in a genome-wide association study of prostate cancer

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix.

When can a risk factor be used as a worthwhile screening test?

Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men.

Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker.

Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus.

P304

363-372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PROS.20887

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Elaine Ostrander

Liesel FitzGerald

P577

2009-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23573041

http://www.w3.org/2001/XMLSchema#string

P698

19058137

http://www.w3.org/2001/XMLSchema#string

P932

2788301

http://www.w3.org/2001/XMLSchema#string